Albemarle (NYSE:ALB) is scheduled to be releasing its earnings data after the market closes on Wednesday, August 7th. Analysts expect Albemarle to post earnings of $1.42 per share for the quarter. Albemarle has set its FY 2019 guidance at $6.10-6.50 EPS and its FY19 guidance at $6.10 to $6.50 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
Albemarle (NYSE:ALB) last released its quarterly earnings results on Wednesday, May 8th. The specialty chemicals company reported $1.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.21 by $0.02. Albemarle had a net margin of 20.54% and a return on equity of 15.53%. The business had revenue of $832.06 million for the quarter, compared to analyst estimates of $827.94 million. During the same period in the previous year, the company earned $1.30 earnings per share. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. On average, analysts expect Albemarle to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
NYSE ALB opened at $65.41 on Tuesday. The business has a fifty day moving average price of $71.23. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 0.36. Albemarle has a 12-month low of $63.10 and a 12-month high of $108.74. The stock has a market capitalization of $7.28 billion, a price-to-earnings ratio of 11.94, a P/E/G ratio of 0.72 and a beta of 1.59.
Several research firms have issued reports on ALB. Loop Capital cut their price target on shares of Albemarle to $108.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. KeyCorp reiterated an “overweight” rating and set a $94.00 price objective (down from $100.00) on shares of Albemarle in a research note on Tuesday, July 9th. ValuEngine downgraded shares of Albemarle from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. Jefferies Financial Group lowered their price objective on shares of Albemarle from $114.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, May 20th. They noted that the move was a valuation call. Finally, TheStreet downgraded shares of Albemarle from a “b-” rating to a “c+” rating in a research note on Monday, May 20th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the company’s stock. Albemarle currently has an average rating of “Hold” and a consensus price target of $95.77.
In related news, SVP Deeanne J. Marlow acquired 1,000 shares of the stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $70.85 per share, for a total transaction of $70,850.00. Following the completion of the purchase, the senior vice president now owns 1,000 shares of the company’s stock, valued at approximately $70,850. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 1.02% of the company’s stock.
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and value-added lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.
Read More: Arbitrage
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.